Innoblative Introduces a Groundbreaking Device for Breast Cancer Patients
SIRA™ RFA Electrosurgical Device (SIRA) from Innoblative is a ground-breaking device for breast cancer patients.
This device has received breakthrough status from the US Food and Drug Administration (FDA).
SIRA is intended for use in breast-conserving surgery (lumpectomy).
Unlike SIRA, conventional RF devices may result in uneven treatment depths and incomplete ablations.
The SIRA device from Innoblative features a unique spherical form that allows for constant and reproducible ablation depths throughout the whole cavity.
The SIRA device is currently being researched for use in breast-conserving surgery and is not yet available for purchase in the United States.